FLASCO

PEMBROLIZUMAB (KEYTRUDA) Is Now Indicated For Recurrent or Metastatic HNSCC

  • FLASCO
  • September 16, 2016

 

FDA granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp.) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Click here for Merck’s announcement

 

 

 

Please Note: DOSAGE AND ADMINISTRATION

  • HNSCC: 200 mg every 3 weeks.
  • Melanoma and NSCLC: 2 mg/kg every 3 weeks.

 

Who’s Online

There are no users currently online